Group 1 - Aktis Oncology Inc. plans to conduct an initial public offering (IPO) in the United States, aiming to raise up to $212 million [1] - The company intends to issue 11.8 million shares at a price range of $16 to $18 per share, potentially valuing the company at approximately $840 million [1] - Aktis specializes in developing alpha particle radiotherapy for solid tumors and was founded in 2021 [1] Group 2 - For the nine months ending September 30, the company reported revenues of $4.6 million and a net loss of $48.6 million, compared to revenues of $554,000 and a net loss of $31.9 million in the same period the previous year [1] - Aktis has raised approximately $346 million from top life sciences investors, including MPM, Vida, EcoR1 Capital, and Blue Owl Capital [2] - The IPO will be led by JPMorgan, Bank of America, Leerink Partners, and TD Securities, with plans to list on the NASDAQ under the ticker symbol AKTS [2]
抗癌生物科技公司Aktis Oncology(AKTS.US)IPO定价16-18美元/股 拟筹资2.12亿美元